Sugi Predict

Sugi Predict / Compounds / SCHEMBL4792269

SCHEMBL4792269

SCHEMBL4792269

Brc1c[nH]c2nccc(-c3ccc(-c4ccccc4)cc3)c12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 10/20 0.58
▸ JAK2 O60674 4/20 0.47
▸ PRKD3 O94806 2/20 0.47
▸ MAP4K4 O95819 2/20 0.47
▸ IGF1R P08069 2/20 0.47
▸ FGFR1 P11362 2/20 0.47
▸ FLT1 P17948 2/20 0.47
▸ KDR P35968 2/20 0.47
▸ MAPK8 P45983 2/20 0.47
▸ CLK2 P49760 2/20 0.47
▸ JAK3 P52333 2/20 0.47
▸ CDK5 Q00535 2/20 0.47
▸ MAP4K2 Q12851 2/20 0.47
▸ DYRK1A Q13627 2/20 0.47
▸ NTRK3 Q16288 2/20 0.47
▸ NTRK2 Q16620 2/20 0.47
▸ AURKB Q96GD4 2/20 0.47
▸ CLK4 Q9HAZ1 2/20 0.47
▸ CDK8 P49336 2/20 0.47
▸ IKBKB O14920 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4790325 0.97 LRRK2 (0.61) LRRK2JAK2PRKD3MAP4K4IGF1R
SCHEMBL31735040 0.82 LRRK2 (0.44) LRRK2JAK2PRKD3MAP4K4IGF1R
SCHEMBL26953045 0.82 LRRK2 (0.44) LRRK2JAK2PRKD3MAP4K4IGF1R
SCHEMBL4792632 0.81 LRRK2 (0.43) LRRK2JAK2PRKD3MAP4K4KDR
SCHEMBL4793527 0.79 LRRK2 (0.48) LRRK2PRKD3MAP4K4KDRMAPK8
SCHEMBL26953049 0.79 LRRK2 (0.44) LRRK2JAK2PRKD3MAP4K4KDR
SCHEMBL14462648 0.78 LRRK2 (0.61) LRRK2JAK2PRKD3MAP4K4IGF1R
SCHEMBL4790877 0.78 LRRK2 (0.61) LRRK2JAK2PRKD3MAP4K4IGF1R
SCHEMBL29957182 0.74 LRRK2 (0.57) LRRK2JAK2PRKD3MAP4K4IGF1R
SCHEMBL29953748 0.74 LRRK2 (0.57) LRRK2JAK2PRKD3MAP4K4IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979353-A2 FUSED HETEROBICYCLIC KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2008-10-15 — — EP claimed
US-20070208053-A1 Fused heterobicyclic kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-09-06 — — US claimed
WO-2007084667-A2 FUSED HETEROBICYCLIC KINASE INHIBITORS OSI PHARMACEUTICAL, INC. (US) 2007-07-26 — — WO claimed
EP-1979353-A2 FUSED HETEROBICYCLIC KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2008-10-15 — — EP disclosed
US-20070208053-A1 Fused heterobicyclic kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-09-06 — — US disclosed
US-20070208053-A1 Fused heterobicyclic kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-09-06 — — US disclosed
US-20070208053-A1 Fused heterobicyclic kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-09-06 — — US disclosed
WO-2007084667-A2 FUSED HETEROBICYCLIC KINASE INHIBITORS OSI PHARMACEUTICAL, INC. (US) 2007-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208053-A1 Fused heterobicyclic kinase inhibitors MAP2K5, MAP2K7, MAP2K2 LRRK2 1655/4885JAK2 272/4885PRKD3 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.